US Corporate Distress Financial Stress SEC Filings — April 02, 2026

02-04-2026

Suncrete, Inc. entered into a Securities Exchange Agreement dated March 26, 2026, to acquire all 26,000,000 Senior Preferred Units of Concrete Partners Holding, LLC from Exchanging Holders in exchange for 26,000 shares of its Series A Convertible Perpetual Preferred Stock at a ratio of 1 share per 1,000 units. The exchange is scheduled to close immediately prior to the Acquisition Merger under the October 9, 2025 Business Combination Agreement with Haymaker Acquisition Corp. 4, with accrued dividends paid in cash beforehand and the transaction structured for tax-deferred treatment under IRC Section 351. No financial valuations or performance metrics are disclosed.

• ·Exchange relies on Section 4(a)(2) of the Securities Act and Rule 506(b) exemption for unregistered issuance to accredited investors.
• ·Permitted under Credit Agreement dated July 29, 2024, as amended October 17, 2025 and subsequently.
• ·Series A Certificate of Designation to be filed with Delaware Secretary of State prior to closing.
• ·Upon closing, all obligations under CPH's Amended and Restated LLC Agreement dated July 29, 2024 are terminated.

02-04-2026

Caris Life Sciences, Inc. entered into a new senior secured Financing Agreement on April 1, 2026, providing a $400,000,000 initial term loan (funded at closing), up to $300,000,000 delayed draw term loan facility (available through August 2027 for permitted acquisitions), and an uncommitted $500,000,000 incremental facility, with lenders including funds managed by Blue Owl Capital and Blackstone. Proceeds from the initial term loan fully repaid and terminated the prior credit agreement dated January 18, 2023. The new facility matures in April 2031, carries interest margins of Term SOFR + 5.00% or Base Rate + 4.00%, and requires maintenance of at least $50,000,000 in minimum qualified cash quarterly.

• ·Obligations guaranteed by certain subsidiaries and secured on a first-priority basis by substantially all tangible and intangible personal property, including pledges of subsidiary capital stock.
• ·New Credit Agreement contains customary covenants limiting debt incurrence, liens, investments, asset dispositions, affiliate transactions, and prepayments of certain indebtedness.
• ·Events of default include payment failures, covenant breaches, bankruptcy, and change of control, allowing lender acceleration.

02-04-2026

OS Therapies completed a $5.25M registered direct offering of common stock and warrants primarily with pre-existing high-net-worth investors at $1.40 per share, with net proceeds plus approximately $4M in expected non-dilutive funds ($2M VAT refunds in 2Q-26 and $2M R&D tax credits in 2H-26) from its U.K. subsidiary providing cash runway into 2027. The company anticipates U.S., U.K., and Europe approvals for OST-HER2 in preventing recurrent pulmonary metastatic osteosarcoma in H2 2026, with upcoming regulatory meetings this quarter and potential eligibility for a Priority Review Voucher (PRV). OST-HER2 holds multiple designations including FDA ODD, FTD, RPDD and EMA ODD, FTD, ATMP, though PRV sale value is uncertain (recent example $205M).

• ·OST-HER2 received Orphan Drug Designation (ODD), Fast Track Designation (FTD), and Rare Pediatric Disease Designation (RPDD) from FDA; ODD, FTD, and ATMP from EMA.
• ·U.K. subsidiary established in 2025 for R&D.
• ·OST-HER2 conditionally approved by USDA for canines with osteosarcoma.
• ·Phase 1b study of OST-504 in castration resistant prostate cancer data expected H1 2026.
• ·Shelf registration on Form S-3 (File No. 333-289443) effective August 25, 2025.

02-04-2026

On March 27, 2026, American Bridge Company, a wholly owned subsidiary of Southland Holdings, Inc., entered into a Settlement Agreement with Clark/Lewis JV, Sureties, Washington State Convention Center, and others, resolving disputes and litigation (King County Superior Court Cause No. 22-2-19603-3 SEA) from the WSCC expansion project. Sureties previously paid $57.8 million for the Merits Judgment (principal ~$57.1 million plus interest) and will pay an additional ~$26.5 million (~$25.5 million for costs/fees/interest, $1.0 million for sanctions). While the settlement provides broad mutual releases and dismissals, it imposes financial obligations consistent with prior estimates, with Sureties forbearing repayment until at least March 27, 2027, amid ongoing negotiations.

• ·Litigation: King County Superior Court Cause No. 22-2-19603-3 SEA
• ·Settlement reserves rights for American Bridge’s appeal of sanctions order
• ·Sureties to receive assignment of Merits Judgment; dismissals with prejudice to follow Satisfaction of Judgment filing
• ·Agreement filed as exhibit to Q1 2026 10-Q
• ·No assurances on final long-term financing agreement for Sureties repayment

02-04-2026

On April 1, 2026, Clearway Energy LLC, Clearway Energy, Inc., and Clearway Energy Group LLC entered into a Third Amended and Restated Exchange Agreement, amending the prior Second Amended Exchange Agreement dated October 28, 2024. The amendment changes the exchange terms, allowing CEG Unitholders to exchange Class B units of Clearway Energy LLC for shares of Class C common stock of Clearway Energy, Inc. (instead of Class A common stock) on a one-for-one basis, subject to equitable adjustments, with corresponding extinguishment of Class B common stock shares. The full agreement is attached as Exhibit 10.1.

• ·Agreement amends and restates the Second Amended Exchange Agreement dated October 28, 2024.
• ·Exchanges remain on a one-for-one basis, subject to equitable adjustments for stock splits, stock dividends, and reclassifications.
• ·Filing date: April 2, 2026; Date of earliest event: April 1, 2026.

02-04-2026

Terra Property Trust, Inc. completed its exchange offers on March 30, 2026, exchanging $24,027,025 of 6.00% unsecured Senior Notes due June 30, 2026, and $1,550,975 of 7.00% unsecured Senior Notes due March 31, 2026 issued by subsidiary TIF6, for $25,578,000 aggregate principal of new 7.00% Senior Secured Notes due March 31, 2029, secured by equity interests in 18 subsidiaries. The new notes carry a 7% interest rate payable monthly starting April 30, 2026, with covenants limiting additional debt and dividends unless a Collateral Coverage Ratio of at least 1.35:1.00 is maintained; no subsidiary guarantees were provided as of issuance.

• ·Exchange Offers expired March 26, 2026, with final settlement on March 30, 2026; TIF6 repaid remaining TIF6 Notes principal on March 31, 2026.
• ·Exchange Notes redeemable at 101% prior to December 31, 2026, and 100% thereafter, plus accrued interest.
• ·Indenture filed as Exhibit 4.1; no requirement to offer purchase on change of control.

02-04-2026

On April 1, 2026, Clearway Energy, Inc., Clearway Energy LLC, and Clearway Energy Group LLC entered into a Third Amended and Restated Exchange Agreement, amending the prior agreement dated October 28, 2024. The amendment changes the exchange provision so that CEG Unitholders may now exchange Class B units of Clearway Energy LLC for shares of Class C common stock (previously Class A common stock) on a one-for-one basis, with corresponding Class B common stock shares extinguished upon exchange. No financial terms or impacts are disclosed in the filing.

• ·Exchange remains subject to equitable adjustments for stock splits, stock dividends, and reclassifications.
• ·Agreement filed as Exhibit 10.1.

02-04-2026

CareView Communications, Inc., along with its subsidiary Borrower, PDL Investment Holdings, LLC as Lender, Steven G. Johnson (President and CEO), and Dr. James R. Higgins (director), entered into the Fourteenth Amendment to the Credit Agreement on March 30, 2026, extending the Maturity Date to June 30, 2026. This amendment continues a long series of prior modifications to the original June 26, 2015 Credit Agreement and related Modification Agreement, with dozens of amendments listed dating back to 2015. The update creates or modifies a direct financial obligation under Item 2.03.

• ·Original Credit Agreement dated June 26, 2015
• ·Filing incorporates 30+ prior amendments to Credit Agreement and Modification Agreement as exhibits, with latest prior ones in December 2025

02-04-2026

Service Properties Trust amended its Declaration of Trust, effective March 30, 2026, to increase total authorized shares of beneficial interest from 300,000,000 to 1,000,000,000, with Common Shares rising from 200,000,000 to 900,000,000 (+350%) while Preferred Shares remain at 100,000,000 (flat). The aggregate par value for Preferred Shares increased from $2,000,000 to $9,000,000 (+350%). The amendment was approved solely by the Board of Trustees, with no shareholder approval required under Maryland REIT Law.

• ·Amendment filed as Exhibit 3.1 in 8-K on April 02, 2026, covering Items 1.01, 5.03, 9.01.
• ·Common Shares have $0.01 par value per share; Preferred Shares without par value.
• ·No shareholder approval required per Section 8-203(a)(8) of Maryland REIT Law and Article V, Section 5.1 of Declaration.

02-04-2026

CytoSorbents Corporation received a 180-day extension from Nasdaq until September 28, 2026, to regain compliance with the Minimum Bid Price Requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), following its initial 180-day period that ended March 31, 2026, without compliance. The extension has no immediate effect on the listing of its Common Stock (CTSO) on Nasdaq Capital Market and does not impact SEC reporting obligations. While the Company intends to monitor the bid price and consider options like a reverse stock split, there is no assurance of regaining compliance, posing a continued delisting risk.

• ·Previous non-compliance notification received October 2, 2025, for 30 consecutive business days of sub-$1.00 closing bid price.
• ·Compliance can be regained if Common Stock bid price closes at $1.00 or higher for minimum 10 consecutive trading days prior to September 28, 2026.
• ·Nasdaq Listing Rule 5810(c)(3)(A) governs the extension.

02-04-2026

Ares Sports, Media & Entertainment Opportunities LP, acting as Servicer, facilitated its subsidiaries (ASME O HOLDINGS I/II/III FINCO LLC as Companies and their LP Parents) entering into a Loan and Security Agreement dated March 27, 2026, with JPMorgan Chase Bank, N.A. as Administrative Agent, The Bank of New York Mellon Trust Company, N.A. as Collateral Agent/Administrator, and various Lenders to finance Portfolio Investments in sports, media, and entertainment assets such as corporate loans, debt securities, music rights securitizations, and equity interests. The facility enables Advances for acquiring these assets via Contribution Agreements from Parents, subject to eligibility criteria, concentration limits, and market value tests. No specific commitment amounts or performance metrics are disclosed in the filing.

• ·Filing items: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits)
• ·Agreement effective as of March 27, 2026; SEC filing date April 02, 2026

02-04-2026

On March 27, 2026, Datasea Inc. received a Nasdaq staff determination notice indicating its common stock (DTSS) failed to comply with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2) for 30 consecutive business days prior to the notice. The company has an initial 180 calendar days until September 23, 2026, to regain compliance by maintaining a $1.00 closing bid price for 10 consecutive business days, with no immediate delisting effect and potential for a second 180-day extension if other listing standards are met. Datasea intends to monitor the stock price and consider options such as a reverse stock split to cure the deficiency.

• ·Nasdaq Listing Rule 5550(a)(2) violated due to 30 consecutive business days below $1.00 bid price
• ·Potential eligibility for second 180-day compliance period requires meeting market value of publicly held shares and other initial listing standards (except bid price)
• ·Company principal executive offices: Room 302-5, Building C, Gemdale Viseen International Center, No. 5 Shengfang Road, Daxing District, Beijing, China 102600

02-04-2026

FibroBiologics, Inc. (NASDAQ: FBLG) announced the pricing of a best efforts public offering of 2,272,728 shares of common stock (or equivalents) and warrants to purchase up to 2,272,728 shares at $1.32 per share and accompanying warrant. The offering is expected to generate approximately $3 million in aggregate gross proceeds before deducting placement agent fees and other expenses, with potential additional gross proceeds of approximately $3 million if the warrants are fully exercised on a cash basis, though no assurance is given that any warrants will be exercised. Closing is expected on or about April 2, 2026, subject to customary conditions, with net proceeds for working capital and general corporate purposes.

• ·Warrants exercisable beginning on effective date of stockholder approval and expire on five-year anniversary thereof
• ·H.C. Wainwright & Co. acting as exclusive placement agent
• ·Securities offered pursuant to registration statement on Form S-1 (File No. 333-294713), effective March 31, 2026
• ·Company focused on therapeutics for chronic diseases including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer

02-04-2026

Hamilton Insurance Group, Ltd. (HG) and its subsidiary Hamilton Re, Ltd. entered into a side letter agreement effective April 1, 2026, with Two Sigma Hamilton Fund, LLC, Two Sigma Principals, LLC, and Two Sigma Investments, LP, terminating a prior commitment agreement dated July 1, 2023 (amended January 1, 2025) and establishing a Minimum Commitment Amount for investment in the Fund as the lesser of $1.8 billion or 60% of HG's net tangible assets. Investor interests are split into Sub-Series A (excess over minimum, withdrawable quarterly with 55 days' notice) and Sub-Series B (up to minimum, withdrawable monthly up to ~8.33% with 6 months' notice or phased over 12 months for larger amounts), with at least 95% of withdrawal proceeds distributed within 25 days. The agreement specifies a default allocation of approximately 70% to equity strategies and 30% to macro strategies, alongside mutual notice obligations for material events like changes in control.

• ·Withdrawal Notice for Sub-Series A: 55 calendar days prior to quarter-end Sub-Series A Withdrawal Date.
• ·Withdrawal Notice for Sub-Series B: 6 months prior to monthly Sub-Series B Withdrawal Date for up to 1/12th; larger withdrawals processed over 12-month schedule starting at 1/12th escalating to 100%.
• ·Notice events include Change in Control (>25% voting interests transfer), material business changes, or adverse law changes.
• ·Prior Commitment Agreement dated July 1, 2023, amended January 1, 2025, terminated effective April 1, 2026.

02-04-2026

Hoth Therapeutics, Inc. entered into a definitive agreement for a registered direct offering of 2,857,144 shares of common stock (or equivalents) at $0.70 per share, expecting aggregate gross proceeds of approximately $2.0 million before fees. In a concurrent private placement, the company issued unregistered warrants to purchase up to 2,857,144 shares at $0.85 per share, potentially providing an additional $2.4 million if fully exercised on a cash basis. Net proceeds will support general corporate purposes, including working capital, with closing expected on or about April 2, 2026.

• ·Offering price: $0.70 per share of common stock (or per common stock equivalent)
• ·Warrant exercise price: $0.85 per share
• ·Warrants exercisable six months after issuance and expire five and one-half years after issuance
• ·Shelf registration on Form S-3 (File No. 333-291566), originally filed November 17, 2015, effective December 4, 2025
• ·H.C. Wainwright & Co. acting as exclusive placement agent

02-04-2026

Vistagen Therapeutics, Inc. notified Nasdaq of non-compliance with Listing Rule 5605(c)(2), which requires an Audit Committee of at least three independent members, following Mary Rotunno's resignation from the Board effective April 1, 2026, reducing the committee to two members. The company's common stock listing on Nasdaq Capital Market remains unaffected, with a cure period extending to the earlier of the next annual stockholders' meeting or one year from the resignation date (or 180 days if the meeting occurs within that timeframe). The Board intends to regain compliance before the cure period expires.

• ·Non-compliance disclosed in prior 8-K filed March 18, 2026.
• ·Nasdaq Listing Rule 5605(c)(2) specifically requires three independent Audit Committee members.
• ·Cure period pursuant to Nasdaq Listing Rule 5605(c)(4)(B).

02-04-2026

On March 27, 2026, Cardiff Oncology, Inc. entered into separation agreements with former CEO Dr. Mark Erlander and former CFO James Levine following their earlier step-downs, entailing significant severance costs including 12 months of base salary continuation ($635,000 for Erlander and $490,000 for Levine), payment of their 2025 bonuses ($122,238 and $61,740 respectively), pro-rated 50% target bonuses for 2026, and up to 12 months of healthcare benefits. Dr. Erlander also signed a consulting agreement with continued stock option vesting until June 2026 and exercisability for 12 months thereafter, while Levine's vested options are exercisable for 12 months post-separation. Dr. Erlander resigned as a director on the same date.

• ·Both executives agreed to general release and confidentiality provisions.
• ·Dr. Erlander's stock options continue to vest until June 2026, then exercisable for 12 months.
• ·Mr. Levine's vested stock options exercisable for 12 months after March 27, 2026.

02-04-2026

Option Care Health, Inc. entered into the Fifth Amendment to its Amended and Restated First Lien Credit Agreement on March 30, 2026, adding $450 million in Incremental Revolving Credit Commitments and increasing total Revolving Credit Commitments to $850 million from a prior $400 million (a 112.5% increase). Bank of America, N.A. serves as administrative agent, with BofA Securities, Inc., JPMorgan Chase Bank, N.A., and Truist Securities, Inc. as joint lead arrangers and bookrunners. The amendment reaffirms all existing guarantees and security interests, with no reported issues such as Events of Default.

• ·Amendment effective upon conditions including execution of documents, legal opinions, certificates of good standing, board resolutions, solvency certificate from CFO, payment of fees, true representations/warranties, no Event of Default, and KYC/PATRIOT Act compliance.
• ·Previous amendments: First (June 8, 2023), Second (December 7, 2023), Third (May 8, 2024), Fourth (September 22, 2025).

02-04-2026

Borealis Foods Inc. entered a Forbearance and Amendment Agreement on March 27, 2026, with Frontwell Capital Partners Inc. to address multiple Specified Defaults under its Credit Agreement, including overadvances, failure to maintain Excess Availability, issuance of $26.7 million in prohibited unsecured notes, and reporting failures, with outstanding Obligations of $16,116,215.30 as of March 25, 2026. The agreement increases financial costs via a default interest rate (up 2.00% since December 9, 2025), higher Applicable Margins (Revolving Loans to 6.50% from 4.50%, Term Loan to 6.75% from 4.75%), a $50,000 forbearance fee, and a $600,000 reserve, while blocking payments on the unsecured notes and requiring milestones like a Refinancing Plan by April 9, 2026. The company appointed Jeffrey T. Varsalone as Chief Restructuring Officer effective March 30, 2026, with broad powers, signaling severe financial distress during the Forbearance Period ending April 27, 2026.

• ·Forbearance Period commences March 27, 2026, and ends April 27, 2026, unless earlier terminated on Forbearance Default.
• ·Milestones include CRO retention by March 30, 2026, and delivery of Refinancing Plan by April 9, 2026.
• ·VRS hourly rates range from $325 to $925 per hour; no success or contingent fees.
• ·Blocked Notes holders include Chairman Barthelemy Helg, CEO Reza Soltanzadeh's controlled entities, and former SPAC sponsor Oxus Capital PTE LTD.

02-04-2026

Silo Pharma, Inc. entered into an asset purchase agreement dated March 31, 2026 (Item 1.01 references July 29, 2025) with Many Ads Inc. to acquire the QwikAgents web-based application software, including source code and object code, along with domain names qwikagents.com, qwikagents.ai, and qwikagents.co. In consideration, the Company issued 2,100,000 shares of its common stock (par value $0.0001 per share) in an unregistered sale under Section 4(a)(2) of the Securities Act. No financial valuation or performance metrics for the assets were disclosed.

• ·Shares have par value $0.0001 per share
• ·Transaction relies on Section 4(a)(2) of the Securities Act for exemption from registration
• ·Seller provides indemnification for misrepresentations, breaches, IP infringement, and gross negligence
• ·Software includes identified Open Source Software components per Exhibit B, with one LGPL-licensed dependency

02-04-2026

Bark, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation, approved by the Board of Directors on March 26, 2026, to implement a 1-for-20 reverse stock split effective at 12:01 a.m. ET on April 1, 2026. The amendment authorizes the Board to select a ratio between 1-for-2 and 1-for-30 shares of Common Stock, with the selected 1-for-20 ratio combining every 20 shares into one, fractional shares rounded down and cashed out at the pre-split closing price on NYSE. The filing was made on April 2, 2026, signed by Chief Legal Officer & Secretary Allison Koehler.

• ·Restated Certificate of Incorporation filed May 30, 2025.
• ·Corporation originally incorporated July 8, 2020.
• ·Common Stock par value $0.0001 per share.

02-04-2026

Nelnet, Inc. entered into a new Credit Agreement dated March 31, 2026, with lenders led by U.S. Bank National Association as Administrative Agent, Wells Fargo Bank, National Association as Syndication Agent, and Royal Bank of Canada as Documentation Agent, including U.S. Bank National Association and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners. The agreement governs revolving loans (CUSIP 64031YAF1) and other facilities (Deal CUSIP 64031YAE4), with standard provisions for commitments, borrowings, covenants, and events of default. No specific commitment amounts or financial terms are detailed in the provided table of contents excerpt.

• ·SEC 8-K filed April 02, 2026, covering Items 1.01 (Entry into Material Definitive Agreement), 1.02, 2.03 (Creation of a Direct Financial Obligation), and 9.01 (Financial Statements and Exhibits)
• ·Exhibit EX-10.1: Execution Version of Credit Agreement

02-04-2026

HMH Holding Inc. priced its initial public offering of 10,520,000 shares of Class A common stock at $20.00 per share, with shares expected to begin trading on Nasdaq Global Select Market under ticker 'HMH' on April 1, 2026, and closing on April 2, 2026. Underwriters have a 30-day option to purchase up to an additional 1,578,000 shares at the IPO price less discounts. No declines or flat metrics reported in this IPO pricing announcement.

• ·Joint lead book-running managers: J.P. Morgan, Piper Sandler, Evercore ISI
• ·Joint book-running managers: Citigroup, DNB Carnegie
• ·Co-managers: Stifel, Nordea, Pickering Energy Partners
• ·SEC registration effective March 31, 2026
• ·HMH provides equipment solutions for oil and gas drilling (offshore/onshore) and expanding to mining

02-04-2026

Cheetah Net Supply Chain Service Inc. entered into a Sales Agreement with AC Sunshine Securities LLC on March 31, 2026, enabling the Company to offer and sell up to $100,000,000 of Class A common stock via an at-the-market offering. Of this, $70,000,000 will be offered pursuant to a prospectus supplement filed April 2, 2026, to an effective Registration Statement. The Sales Agent will receive a 3.0% commission on gross proceeds and reimbursements for specified expenses up to $100,000 initially.

• ·Sales permitted by methods including direct on Nasdaq Capital Market or through market makers, as an 'at the market offering' under Rule 415(a)(4).
• ·Registration Statement filed August 28, 2024, effective September 6, 2024.
• ·Exhibits include Sales Agreement (10.1), legal opinion (5.1), and consent (23.1).

02-04-2026

Gulf Resources, Inc. entered into four private placement agreements on January 26, March 5, March 19, and March 28, 2026, issuing 274,000 shares of common stock to four individual investors for total proceeds of US$1,035,880, representing approximately 18% of shares outstanding as of December 31, 2025. The shares were sold at discounts (90% of 5-day average closing price for January; 85% of prior-day close for March) to enhance liquidity and market value. While providing needed capital, the transactions cause significant dilution to existing shareholders.

• ·Private placement shares issued pursuant to exemption under Section 4(a)(2) of the Securities Act and/or Regulation D.
• ·Funds to be used exclusively for company operations and development.
• ·Investors subject to 6-month lock-up on share transfers.

02-04-2026

Plus Therapeutics, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, effective April 2, 2026, authorizing 205,000,000 total shares consisting of 200,000,000 shares of Common Stock (par value $0.001) and 5,000,000 shares of Preferred Stock (par value $0.001). The amendment implements a 1-for-25 reverse stock split of Common Stock at 12:01 a.m. EST on the effective date, with no fractional shares issued and cash payments in lieu thereof based on fair market value. Approvals were obtained from the Board on July 25, 2025 and March 20, 2026, and from stockholders at the 2025 Annual Meeting on August 7, 2025.

02-04-2026

Norfolk Southern Corporation, through its subsidiary Norfolk Southern Railway Company (NSRC), entered into amended and restated agreements on April 1, 2026, to renew the lease for its corporate headquarters building at 650 West Peachtree Street NW, Atlanta, Georgia, for an additional five-year term with an aggregate lease amount of approximately $498.7 million. The transaction consolidates all interests with BA Leasing BSC, LLC (BAL) as the sole counterparty, structures the lease as a finance lease (previously operating), and requires monthly rent based on Term SOFR plus an applicable margin under a triple-net arrangement. The parent company provides an unconditional guaranty for NSRC's obligations, with options at term end to extend, purchase, or sell the building.

• ·Lease base term: five years commencing April 1, 2026
• ·Original agreements dated March 1, 2019
• ·At least 90 days prior to end of base term, NSRC must elect to extend for five years (with consent), purchase the building, or arrange third-party sale (if not in default)
• ·Triple-net lease: NSRC responsible for maintenance, insurance, property taxes, and operating costs

02-04-2026

Public Storage and subsidiary Public Storage Operating Company entered into an underwriting agreement on April 1, 2026, with BofA Securities, Inc. and J.P. Morgan Securities LLC for the sale of $500 million aggregate principal amount of 5.000% senior notes due December 15, 2035, issued at 99.182% of par and guaranteed by Public Storage. Proceeds will repay the revolving credit facility and fund general corporate purposes, including self-storage facility investments, debt repayment, and securities redemptions. The offering is expected to close on April 6, 2026, subject to customary conditions.

• ·Interest payable semi-annually on June 15 and December 15, commencing June 15, 2026.
• ·Offering pursuant to shelf registration on Form S-3 filed December 2, 2024.
• ·Underwriters include affiliates of lenders under PSOC’s revolving credit facility.

02-04-2026

Business First Bancshares, Inc. (BFST) filed an 8-K on April 02, 2026, disclosing entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation (Item 2.03), accompanied by Regulation FD disclosure (Item 7.01) and Exhibit 99.1. No specific financial figures, performance metrics, or details on the agreement were provided in the extractable text. The exhibit appears to be an image, limiting further analysis.

• ·Filing Type: 8-K
• ·Items: 1.01 (Material Definitive Agreement), 2.03 (Direct Financial Obligation), 7.01 (Regulation FD Disclosure), 9.01 (Financial Statements and Exhibits)
• ·Subcategory: Material Agreement Entry
• ·Exhibit: 99.1 (image format)

02-04-2026

Summit Midstream Corporation (NYSE: SMC) entered into a securities purchase agreement with an affiliate of Tailwater Capital LLC for a private placement of 1,351,351 shares of common stock at $31.08 per share, raising $42.0 million. The proceeds will reduce borrowings under the asset-based lending credit facility and fund organic growth capital projects, strengthening the balance sheet and supporting the long-term 3.5x leverage target. Post-transaction, Tailwater and affiliates will beneficially own approximately 39% of Summit's outstanding equity.

• ·Shares subject to a 6-month lock-up period.
• ·Transaction unanimously approved by the Audit Committee of independent directors.
• ·Price per share of $31.08 represents closing price as of March 30, 2026.
• ·Tailwater Capital has raised more than $6 billion in committed equity capital and executed more than 300 transactions representing over $29 billion in value.

02-04-2026

Tigo Energy, Inc. entered into a Credit Agreement dated March 31, 2026, with Wells Fargo Bank, National Association as lender, establishing an asset-based revolving credit facility determined by a borrowing base of eligible accounts receivable and inventory. Tigo Energy MergeCo, Inc. serves as guarantor. The facility includes advances of up to 85% on domestic eligible accounts, a $4,000,000 cap on foreign accounts, and a $1,500,000 cap on in-transit inventory, with interest rates based on SOFR plus 1.75-2.00% or Base Rate plus 0.75-1.00% depending on excess availability tiers.

• ·Borrowing Base excludes Inventory subject to third-party intellectual property rights until licensor consent is obtained.
• ·Facility includes letter of credit subfacility and provisions for bank products.
• ·Financial covenant requires maintenance of Liquidity (details not specified in excerpt).

02-04-2026

On March 28, 2026, Beyond Meat entered into a Sales Agreement with Roquette Frères for pea protein supply, committing to minimum annual purchases totaling approximately $23.5 million over 2026-2027, secured by a $1.0 million standby letter of credit, with potential liquidated damages for shortfalls. The board also approved the 2026 Employment Inducement Equity Incentive Plan effective March 30, 2026, reserving 10,000,000 shares of common stock for new employees without stockholder approval. No operational or financial performance metrics are disclosed.

• ·Sales Agreement expires December 31, 2027, subject to extension or early termination.
• ·Inducement Plan prohibits incentive stock options and limits awards to new employees per Nasdaq Rule 5635(c)(4).

02-04-2026

New Fortress Energy Inc. entered into the LCF Forbearance Agreement on March 27, 2026, with lenders under the Letter of Credit Agreement (dated July 16, 2021), whereby lenders agreed to forbear from exercising rights and remedies on specified defaults until September 15, 2026. The agreement aligns with the Restructuring Support Agreement (RSA) signed on March 17, 2026, to support recapitalization of the company's indebtedness. Without further forbearance post-termination, the company could face requirements to cash collateralize outstanding principal and other obligations under the facility.

• ·Letter of Credit Agreement originally dated July 16, 2021.
• ·8-K filed on April 2, 2026, reporting event of March 27, 2026.
• ·Soliciting material pursuant to Rule 14a-12.

02-04-2026

KPET Ultra Paceline Corporation, a blank check company (SPAC), announced the pricing of its IPO of 20,000,000 units at $10.00 per unit, generating $200,000,000 in gross proceeds, with trading to commence on NYSE under 'KPET.U' on March 31, 2026. Deutsche Bank Securities Inc. serves as sole book-running manager and has a 45-day option to purchase up to an additional 3,000,000 units. Each unit includes one Class A ordinary share and one-sixth of a redeemable warrant exercisable at $11.50 per share.

• ·Units to separate trade with Class A shares under 'KPET' and warrants under 'KPET.WS'
• ·SEC registration statement declared effective March 30, 2026
• ·Sponsored by KPET Ultra Paceline LLC; sponsor is a family office with diversified portfolio
• ·Past investment in IRA Financial, a South Dakota-chartered trust company specializing in self-directed retirement accounts for alternative assets

02-04-2026

FGI Industries Inc., a subsidiary of FGI Industries Ltd., entered into an Amended and Restated Business Loan Agreement (Asset Based) with East West Bank on March 27, 2026, providing for a line of credit with advances available up to the Borrowing Base, subject to conditions precedent including perfection of security interests in collateral such as accounts receivable and inventory. The agreement is secured by liens on Borrower's assets, requires ongoing compliance certificates and audits, and continues until all obligations are paid in full. No specific loan amounts or borrowing limits were disclosed in the filing.

• ·SEC 8-K filing dated April 02, 2026, covering Items 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), and 9.01 (Financial Statements and Exhibits).
• ·Collateral includes Accounts, Inventory, and related proceeds; Lender has rights to audit, notify account debtors, and collect payments directly.
• ·Conditions precedent include execution of related documents such as Note, Security Agreements, Guaranties, and perfection certificates.

02-04-2026

On April 2, 2026, the NYSE notified Solo Brands, Inc. that it will commence delisting proceedings for its Class A common stock due to failure to maintain an average global market capitalization of at least $15 million over 30 trading days under Rule 802.01B, with trading suspended after market close. The stock is expected to begin trading on the OTCQB Venture Market on April 6, 2026, under symbol 'SBDS', though liquidity and market-making are not guaranteed. CEO John Larson emphasized that operations, strategic priorities, and financial position remain unchanged, with a sound balance sheet, debt covenant compliance, and ongoing focus on cash flow generation and profitability improvements.

• ·Company has right to appeal delisting to NYSE Board of Directors Committee and is evaluating the option.
• ·If no appeal or unsuccessful, NYSE will file Form 25 with SEC; delisting effective 10 days after filing.
• ·Registrant is an emerging growth company.
• ·Class A Common Stock has $0.001 par value per share.

02-04-2026

Fusemachines Inc. received a Nasdaq deficiency notice on March 27, 2026, stating that its securities failed to maintain the minimum Market Value of Listed Securities (MVLS) of $50,000,000 for 30 consecutive business days, per Listing Rule 5450(b)(2)(A). There is no immediate impact on listing, with common stock (FUSE) and warrants (FUSEW) continuing to trade, and the company has 180 calendar days until September 23, 2026, to regain compliance by achieving the MVLS threshold for 10 consecutive business days. The company plans to monitor its MVLS and explore options to comply, though success is not guaranteed amid market and operational risks.

• ·Nasdaq compliance determination based on last 30 consecutive business days prior to March 27, 2026
• ·Company classified as emerging growth company

02-04-2026

Nuveen Churchill Private Capital Income Fund (PCAP) announced it will acquire 100% of the assets and liabilities of Nuveen Churchill BDC V (BDC V) at fair value (net asset value), with the transaction expected to close in Q2 2026 subject to shareholder approval and customary conditions. The deal is anticipated to enhance PCAP's scale, portfolio diversification (top 10 investments dropping from ~11% to ~9% of portfolio), and operational efficiencies, with BDC V's complementary portfolio showing 55% asset overlap, no non-accrual investments, and a weighted average internal risk rating of 4.0 as of December 31, 2025. While positioned for long-term value, the transaction carries risks including potential failure to close, shareholder rejection, and economic disruptions.

• ·BDC V commenced operations in August 2025.
• ·Transaction consideration: cash equal to BDC V’s NAV as of a date no earlier than 48 hours prior to closing.
• ·PCAP and BDC V focus on U.S. middle market companies with $10 to $100 million EBITDA.
• ·Proxy statement to be filed by BDC V for shareholder approval of transaction and BDC election withdrawal.

02-04-2026

Nuveen Churchill Private Capital Income Fund (PCAP) will acquire 100% of the assets and liabilities of Nuveen Churchill BDC V (BDC V) at fair value pursuant to a purchase and sale agreement, with closing expected in Q2 2026 subject to approvals including BDC V shareholder vote. The transaction enhances PCAP's scale, portfolio diversification (top 10 investments ~9% post-transaction vs. ~11% pre-transaction), operational efficiency, and access to capital, while enabling an efficient wind-down of BDC V. BDC V's complementary portfolio has no non-accrual investments and a weighted average internal risk rating of 4.0 as of December 31, 2025, with ~55% already held in PCAP.

• ·BDC V commenced operations in August 2025
• ·No investments on non-accrual in BDC V’s portfolio as of December 31, 2025
• ·Weighted average internal risk rating of BDC V portfolio: 4.0 as of December 31, 2025
• ·Transaction consideration: cash equal to BDC V’s net asset value as of date no earlier than 48 hours prior to closing

02-04-2026

Veea Inc., a Delaware corporation, designated 212,000 shares of Series A Convertible Preferred Stock (par value $0.0001), each with a stated value of $100, via unanimous board consent dated March 30, 2026, filed as Exhibit 3.2 in an 8-K on April 02, 2026. Each Series A share is convertible into 198 shares of common stock at a conversion price of $0.503, subject to adjustments for stock splits, dividends, and distributions, with the company required to reserve sufficient common shares for conversion. The filing covers Items 1.01 (material agreement), 3.01 (potential delisting notice), 3.02 (material impairments), 5.03 (articles amendment), and 9.01 (exhibits), indicating broader corporate developments.

• ·Board of Directors unanimous written consent dated March 30, 2026
• ·Conversion subject to Trading Market rules and Exchange Cap limitations unless stockholder approval obtained
• ·Corporation covenants to reserve 100% of Conversion Shares from authorized common stock
• ·No dividends on Series A Preferred except pro-rata as-if-converted to common stock
• ·Adjustments to Conversion Price for stock dividends, splits, combinations, or reclassifications

02-04-2026

United Natural Foods, Inc. entered into an Amended and Restated ABL Credit Facility effective April 1, 2026, reducing the revolving credit commitment from $2,600 million to $2,400 million (including a $100 million CAD sublimit) while retaining the $130 million FILO tranche and adding an option to increase by up to $750 million, with maturity extended to April 1, 2031. Interest margins are lower initially (e.g., Term SOFR +1.125%), but the facility includes covenants like a 1.0x fixed charge coverage ratio if availability falls below the greater of $204 million or 10% of the borrowing base. The agreement is secured by first-priority liens on ABL assets and replaces the prior facility dated June 3, 2022.

• ·ABL Credit Facility maturity: April 1, 2031, subject to springs 91 days prior to $500M term loan (October 22, 2018) or 6.750% senior notes due 2028 maturities if >$100M outstanding (with exceptions).
• ·Borrowing base: 90% eligible AR + 90% eligible credit card receivables + 90.0% (or 92.5%) eligible inventory NOLV + 90% eligible pharmacy receivables + 85% certain pharmacy prescription files, net of reserves; capped at lesser of commitments or borrowing base.
• ·Guaranteed by most wholly-owned subsidiaries; first-priority lien on ABL assets (AR, inventory, deposit accounts), second-priority on other assets.

02-04-2026

Bed Bath & Beyond closed the acquisition of Kirkland’s (over 230 locations) and signed definitive agreements to acquire The Container Store (over 100 trophy locations, 2.2 million sq ft), Elfa, and Closet Works, expected to close in July 2026 and deliver at least $40M in annualized cost savings within 12-18 months. The company reported early signs of revenue growth and earnings improvement in Q1 2026 vs. Q1 2025. Leadership updates include appointments of Amy Sullivan as President, Lisa Foley as COO, Brian LaRose as CFO, and Anders Hahn as CEO of Elfa, alongside the departure of Adrianne Lee at the end of April.

• ·Transaction consideration includes common stock at $7.00 per share and convertible notes at $9.10 per share
• ·The Container Store locations to be rebranded as The Container Store / Bed Bath & Beyond with expanded services including flooring, lighting, kitchen, laundry, and bathroom cabinetry
• ·Acquisitions aligned with three-pillar strategy; Kirkland’s enhances home décor and seasonal merchandise
• ·Elfa based in Malmö, Sweden; Closet Works in greater Chicago area; The Container Store founded in Dallas, Texas

02-04-2026

Nexstar Media Inc., a wholly owned subsidiary of Nexstar Media Group, Inc., completed the issuance and sale of $1,725 million in aggregate principal amount of 7.250% Senior Notes due 2034 in a private offering exempt from Securities Act registration. The proceeds were used to fund the redemption of the Issuer’s 5.625% Senior Notes due 2027 and pay related fees and expenses. The notes are guaranteed on a senior unsecured basis by the Company, Mission Broadcasting, Inc., and certain subsidiaries, ranking equal with existing senior indebtedness.

• ·Notes mature on April 15, 2034, with interest accruing at 7.250% per annum, payable semiannually on April 15 and October 15, commencing October 15, 2026.
• ·Issuer may redeem notes prior to April 15, 2029, at 100% principal plus make-whole premium, or up to 40% at 107.250% with equity offering proceeds; on or after April 15, 2029, at prices set in indenture.
• ·Upon Change of Control Repurchase Event, holders may require repurchase at 101% of principal plus accrued interest.
• ·Indenture includes covenants limiting debt incurrence, dividends, investments, liens, mergers, asset sales, and subsidiary distributions, with exceptions.

02-04-2026

Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced the commencement of an underwritten public offering of common stock shares, with underwriters granted a 30-day option to purchase up to an additional 15% of the shares. The company intends to use net proceeds, along with existing cash, to fund commercial readiness and potential launch of barzolvolimab for chronic spontaneous urticaria (CSU) if approved, pipeline development including the bispecific antibody platform, and general corporate purposes. Final terms depend on market conditions, with no assurance of completion, size, or timing.

• ·Shelf registration statement on Form S-3 (File No. 333-275300) became effective November 3, 2023.
• ·Announcement dated April 1, 2026; 8-K filing date April 2, 2026.
• ·References Form 10-K for year ended December 31, 2025.

02-04-2026

Commercial Vehicle Group (CVGI) completed a sale-leaseback transaction for its Vonore, Tennessee manufacturing facility, generating $16 million in proceeds used to prepay a portion of its existing term loan and reduce leverage. The company will lease back the property for a 20-year term with an initial annual base rent of approximately $1.4 million, anticipating no operational disruptions. CVG reaffirmed its full-year 2026 outlook previously issued on March 10, 2026.

• ·Manufacturing facility location: Vonore, Tennessee
• ·Announcement date: April 2, 2026
• ·Prior outlook issuance date: March 10, 2026

02-04-2026

Auddia Inc. amended its Certificate of Incorporation to implement a reverse stock split, effective March 31, 2026, at 5:00 p.m. ET, whereby every 7.7 shares of existing common stock are automatically converted into one share of new common stock. Fractional shares resulting from the split will be rounded up to one whole share, with the amendment approved by stockholders and filed on March 30, 2026.

• ·Original Certificate of Incorporation filed February 16, 2021
• ·Amendment filed March 30, 2026, at 3:28 p.m. with Delaware Secretary of State (SR# 20261530949, File Number 5096256)
• ·8-K filing date: April 02, 2026; Items: 3.03, 5.03, 9.01

02-04-2026

USBC, Inc. completed the divestiture of its legacy sensor technology business effective March 27, 2026, to a newly-formed entity controlled by former Chairman and CEO Ron Erickson, who departed his roles as USBC Science Division President and Board member at closing. The transaction includes a revenue-sharing arrangement for USBC to retain economic interest and a short-term bridge loan facility of up to $450,000 to the buyer. This move simplifies operations and reallocates capital toward USBC's core focus on tokenized deposit offerings.

• ·Transaction details available in Form 8-K and at https://investors.usbc.xyz
• ·USBC tokenized deposit whitepaper: http://usbc.xyz/i/whitepaper

02-04-2026

Oncotelic Therapeutics, Inc. announced a strategic partnership with TechForce Robotics, Inc. to commercialize its PDAOAI-enhanced GMP-compliant robotics platform for pharmaceutical manufacturing, combining Oncotelic's AI capabilities with TechForce's robotics hardware. The partnership follows a joint development, manufacturing, and licensing agreement aimed at automating workflows, reducing contamination risks, and ensuring regulatory compliance. This milestone positions the platform to address growing demand for AI-driven automation in regulated industries.

• ·Filing date: April 02, 2026
• ·Oncotelic owns 45% of GMP Bio, a joint venture advancing oncology and rare disease therapeutics
• ·Dr. Vuong Trieu has filed over 500 patent applications and holds 75 issued U.S. patents

02-04-2026

Virtuix Holdings Inc. entered into an Exchange Agreement dated March 31, 2026, with Streeterville Capital, LLC, to exchange prior 2024 Subordinated Promissory Notes (originally issued between July 15, 2024, and December 10, 2024) for a new Exchange Note with an original principal amount of $2,681,718.42. The transaction qualifies under Section 3(a)(9) of the Securities Act, with the Exchange Note guaranteed by subsidiary Virtuix, Inc., and no additional consideration provided beyond surrendering the prior notes. The exchange consolidates the company's debt obligations to the Holder without novation.

• ·Prior Notes purchased by Holder pursuant to Note Purchase Agreements dated March 30, 2026.
• ·Prior Notes amendments: Amendment No. 1 dated August 8, 2024; Amendment No. 2 dated June 18, 2025; Amendment No. 3 dated December 11, 2025.
• ·Exchange intended to preserve holding period under Rule 144 from original Issuance Dates.

02-04-2026

Trans American Aquaculture, Inc. entered into a Securities Purchase Agreement with GHS Investments LLC on March 26, 2026, selling 59 shares of Series D Preferred Stock at $1,000 per share for an aggregate $59,000, issuing 6 additional commitment shares, and warrants to purchase 243,750,000 shares of common stock at $0.000161 per share. The Series D Preferred Stock has a $1,200 stated value per share and accrues 8% annual dividends, paid quarterly in cash or shares at the company's discretion. Subject to conditions including filing the 10-K for FY ended December 31, 2025, up to 13 additional shares may be sold at GHS's discretion.

• ·Warrants issued contain full-ratchet anti-dilution provisions and expire March 26, 2031.
• ·Sales made in reliance on Section 4(a)(2) of Securities Act and Rule 506 of Regulation D; no commissions paid.
• ·$3,000 legal fees may be paid in cash or Series D Preferred Stock.
• ·GHS represented as accredited investor.